CancerDrs

Lymphoma clinical trials in District of Columbia

19 actively recruiting lymphoma trials at 1 site across District of Columbia.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in District of Columbia:
  • MedStar Georgetown University Hospital — Washington D.C., District of Columbia
  • Children's National Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Industry

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refracto…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06084936
Sites in District of Columbia:
  • Georgetown University — Washington D.C., District of Columbia
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in District of Columbia:
  • Children's National Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Academic/Other

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…

Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in District of Columbia:
  • MedStar Georgetown University Hospital — Washington D.C., District of Columbia
  • Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may st…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT04803201
Sites in District of Columbia:
  • MedStar Georgetown University Hospital — Washington D.C., District of Columbia
Phase 2 Recruiting Industry

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal re…

Sponsor: Allogene Therapeutics
NCT ID: NCT06500273
Sites in District of Columbia:
  • MedStar Georgetown University Hospital — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- posi…

Sponsor: Nuvalent Inc.
NCT ID: NCT05384626
Sites in District of Columbia:
  • Georgetown University Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in District of Columbia:
  • Children's National Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…

Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in District of Columbia:
  • The George Washington University Cancer Center (site 212) — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other

A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05389293
Sites in District of Columbia:
  • Georgetown University (Data Collection Only) — Washington D.C., District of Columbia
Phase 1 Recruiting NIH

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in District of Columbia:
  • MedStar Georgetown University Hospital — Washington D.C., District of Columbia
Phase 1 Recruiting Academic/Other

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolesce…

Sponsor: New York Medical College
NCT ID: NCT04972942
Sites in District of Columbia:
  • Children's National Medical Center — Washington D.C., District of Columbia
EARLY Phase 1 Recruiting Academic/Other

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with che…

Sponsor: Nationwide Children's Hospital
NCT ID: NCT06333899
Sites in District of Columbia:
  • Children's National Medical Center — Washington D.C., District of Columbia
Recruiting Network

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in District of Columbia:
  • Children's National Medical Center — Washington D.C., District of Columbia
Recruiting Network

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)-related cancers. Collecting blood and tissue samples and studying biomarkers in the laboratory may he…

Sponsor: AIDS Malignancy Consortium
NCT ID: NCT05663502
Sites in District of Columbia:
  • George Washington University — Washington D.C., District of Columbia
NA Recruiting Academic/Other

Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses

This study is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay in treatment for opioid use disorder (OUD) than referring them to community buprenorphine treatment…

Sponsor: Montefiore Medical Center
NCT ID: NCT07631598
Sites in District of Columbia:
  • HIPS — Washington D.C., District of Columbia
NA Recruiting Academic/Other

Massage Impact on Sleep in Pediatric Oncology

This study aims to determine the impact of massage therapy for pediatric patients receiving intensive chemotherapy or stem cell transplant (SCT).

Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT06892158
Sites in District of Columbia:
  • Children's National Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other

Virtual Reality During Lumbar Punctures in Acute Lymphoblastic Leukemia

Over 90% of children and adolescents diagnosed with acute lymphoblastic leukemia (ALL) will survive long term. Part of the successful treatment that patients receive is the delivery of chemotherapy directly into their spinal fluid via a sp…

Sponsor: Children's National Research Institute
NCT ID: NCT06722638
Sites in District of Columbia:
  • Children's National Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other

Feasibility/Acceptability of Attentional-Control Training in Survivors

This is a multicenter pilot randomized controlled trial, with an active control condition, of the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a cohort of survivors of acute lymphoblastic leukemia or brain tumor ag…

Sponsor: Children's National Research Institute
NCT ID: NCT05528939
Sites in District of Columbia:
  • Children's National Hospital — Washington D.C., District of Columbia

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-09-07